CVS Prescribes Growth

Recs

0

The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins. CVS (NYSE: CVS) announced a 24.6% increase in earnings to $244.6 million for the first quarter.

CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways. It expects to finalize its acquisition of 1,260 Eckerd drug stores (currently owned by J.C. Penney (NYSE: JCP)) next month. If approved (I see no reason why it won't get approved), the company would surpass Walgreen (NYSE: WAG) as the No. 1 drugstore chain, with approximately 5,400 locations.

The company also made camera phone photo printing available in all CVS stores with one-hour photo services. CVS became the first national retailer to provide this option. The company expects this service to bring in new customers to its stores as it did with digital photo customers (13% of the company's digital photo customers were new to CVS). Camera phone sales are expected to increase from 7.5 million to 21.3 million by the end of the year, according to figures quoted by the company.

The company also released its statement of cash flows this morning, which Fools mightily appreciate. It produced $126.6 million in free cash flow for the quarter, substantially ahead of last year's $7.6 million.

In addition to the remarkable earnings and free cash flow growth, CVS reported an increase in same-store sales of 6.4%, while total revenues rose 8% to $6.82 billion. The company's gross margins expanded impressively to 26% from 25%

With this type of performance, one might expect the stock to come at an outrageous price. Well, with CVS, that's not the case. Though it's trading near its 52-week high and may cross it today, it's still a relative value at just under $40. Its forward P/E of 19.3 compares very favorably to competitor Walgreen, which is trading at 26.9 times forward earnings. I may not have paid much attention to it in the past, but I'm certainly going to keep an eye on CVS in the future.

What's your opinion on CVS? Did it do the smart thing by buying Eckerd? Will you go get your camera phone pics developed there? Talk about it on the CVS discussion board.

Fool contributor Mike Cianciolo welcomes feedback and doesn't own any of the companies mentioned in this article.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 507500, ~/Articles/ArticleHandler.aspx, 12/2/2009 6:24:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Fool Search: Be GM's Next CEO!

By The Motley Fool

Fool Search: Be GM's Next CEO!

Related Tickers

12/2/2009 4:01 PM
CVS $31.11 Down -0.07 -0.22%
CVS Caremark Corp CAPS Rating: ****
JCP $29.17 Up +0.36 +1.25%
J.C. Penney Compan… CAPS Rating: **
WAG $38.20 Down -1.17 -2.97%
Walgreen Company CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Celanese: Celanese (NYSE: http://caps.fool.com/Ticker/CE.aspx CE) is an integrated global producer of value-added industrial chemicals; a producer of acetyl products, including acetic acid, vinyl acetate monomer and polyacetal products; and a global producer of engineered polymers.

Want to learn more or edit this definition?
Click here to read more!